A new position statement from the International Diabetes Federation advises using a 1-hour 75-g oral glucose tolerance test (OGTT) to improve identification of people at risk […]

TOPLINE: Higher weekly levels of moderate physical activity are associated with a lower risk for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) […]

The US Food and Drug Administration (FDA) has approved the anti-obesity drug semaglutide 2.4 mg injection (Wegovy) for reducing cardiovascular risk in adults with overweight or […]

COPENHAGEN (Reuters) – Novo Nordisk’s CEO on Friday said compounded semaglutide in the United States is a serious health issue. Demand for Novo’s wildly popular weight-loss […]

(Reuters) -Novo Nordisk’s CEO on Friday said the company was working with authorities in several countries to tackle counterfeit versions of its popular diabetes drug Ozempic, […]

TOPLINE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors may surpass other oral antidiabetic drugs in metabolic dysfunction–associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease […]

COPENHAGEN (Reuters) -Novo Nordisk on Thursday surpassed Tesla Inc in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data […]

TOPLINE: Home or hospital insulin pumps are safe and improve glucose control in pediatric, adolescent, and young adult patients with type 1 diabetes hospitalized for noncritical […]

TOPLINE: A fiber supplement also found in beans and other foods may lead to weight loss and improved insulin sensitivity in people with excess body weight, […]